Statistically sig­nif­i­cant im­prove­ment in pro­gres­sion-free survival dem­onstrated

Boudry, Switzerland (Press Release) - Celgene Inter­na­tional Sàrl, a wholly-owned sub­sid­i­ary of Celgene Corpo­ra­tion (NASDAQ: CELG), today announced that its phase III study (MM-020/IFM 07-01) of REVLIMID^® (lena­lido­mide) in com­bi­na­tion with dexa­meth­a­sone in patients newly diag­nosed with multiple myeloma met its pri­mary end­point of pro­gres­sion-free survival (PFS). In the study, a doublet regi­men of continuous oral lena­lido­mide in com­bi­na­tion with low-dose dexa­meth­a­sone (Rd) dem­onstrated a statistically sig­nif­i­cant im­prove­ment in PFS compared to patients receiving a comparator arm with a triplet regi­men consisting of mel­phalan, pred­ni­sone and thalido­mide (MPT).

One of the largest phase III …

Cancer Treatment Centers of America at Eastern Regional Medical Center Expands its Stem Cell Transplant & Cell Therapy Program, Draws Patients from Across the Northeast

Philadelphia (Press Release) - Cancer Treatment Centers of America (CTCA) at Eastern Regional Medical Center proudly opened its new stem cell trans­plant center to patients with hema­to­logic malig­nan­cies today. The 17,000 square foot center in­cludes eight state-of-the-art inpatient rooms, along with a dedicated in­fu­sion suite and apheresis and stem cell collection unit.

Under the leadership of highly regarded hematologist-oncologists Dr. Pamela Crilley and Dr. David Topol­sky, the expanded Stem Cell …

White Plains, NY (Press Release) - The Leukemia & Lymphoma Society (LLS) today announced a col­lab­o­ra­tion with Johns Hopkins University School of Medicine to ad­vance a novel adoptive immuno­therapy for patients with poor prognosis myeloma, a blood cancer. The ap­proach shows promise for patients with other blood cancers as well.

Under the leadership of Ivan Borrello, M.D., Johns Hopkins Kimmel Cancer Center, a team of researchers is testing a method using marrow-infiltrating lym­pho­cytes (MILs) – immune T cells that are specifically trained to recog­nize and kill myeloma cells. MILs are produced from a …

Board of Directors Rejects $120 per Share Proposal as Significantly Undervaluing Company

South San Francisco, CA (Press Release) - Onyx Pharma­ceu­ticals, Inc. (NASDAQ: ONXX) today con­firmed that it has received and rejected an unsolicited proposal from Amgen Inc. to acquire all of Onyx's outstanding shares and share equivalents for $120 per share in cash, subject to due diligence and other con­di­tions. The Board of Directors of Onyx had eval­u­ated the proposal made by Amgen with the assistance of its financial and legal advisors and concluded that the price proposed by Amgen sig­nif­i­cantly undervalued Onyx and its prospects, and was not in the best …

Label updates could lead to sig­nif­i­cantly im­proved out­comes for patients with multiple myeloma

Beerse, Belgium (Press Release) - Janssen-Cilag Inter­na­tional NV (Janssen) announced today that The Committee for Medical Products for Human Use (CHMP) of The European Medicines Agency (EMA) has granted a positive opinion on two variations relating to the use of VELCADE®.[1] VELCADE® is indicated for the treat­ment of multiple myeloma, a type of blood cancer.

The first recom­men­da­tion is for the use of VELCADE® (bor­tez­o­mib) as retreatment in adult patients who have pre­vi­ously responded to treat­ment with the same medicine.¹ The positive opinion re-enforces the ex­ist­ing data sup­porting the use of VELCADE® in this wider re­lapsed patient …

Development of novel thera­peutic anti­body ap­proach being eval­u­ated in clin­i­cal trials for patients with multiple myeloma

MorphoSys will hold a conference call on Thursday, June 27, at 4:00pm CEST (3:00pm GMT/10:00am EDT)

• Celgene secures worldwide rights to MOR202, whereby the companies will jointly develop MOR202 globally and co-promote the product in Europe
• MorphoSys retains a 50/50 profit sharing in its co-promotion territory and is eligible to receive tiered double-digit royalties outside of the co-promotion territory

Martinsried and Munich, Germany and Summit, NJ (Press Release) – MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) and Celgene Corpo­ra­tion (NASDAQ: CELG) today announced an agree­ment to jointly develop MOR202 globally and to co-promote MOR202 in Europe. MOR202 is a fully human mono­clonal anti­body targeting CD38 to treat patients with multiple myeloma (MM) and certain leukemias. MOR202 is cur­rently being eval­u­ated in a phase 1/2a trial in patients with re­lapsed / refractory myeloma. MorphoSys and Celgene will col­lab­o­rate on the devel­op­ment of MOR202 in multiple myeloma and other …

• Median progression-free survival (PFS) of 33 months reached after longer-term follow up in patients treated with elotuzumab 10 mg/kg plus lenalidomide and low-dose dexamethasone
• Longer-term safety profile of the combination consistent with previously reported results
• Results Presented at 18th Annual Congress of the European Hematology Association
• Two Phase 3 studies of elotuzumab at 10 mg/kg dose ongoing in patients with previously-treated and newly-diagnosed multiple myeloma

Princeton, NJ and North Chicago, IL (Press Release) – Bristol-Myers Squibb Com­pany (NYSE: BMY) and AbbVie (NYSE: ABBV) to­day an­nounced up­dated ef­fi­cacy and safety data from a small, ran­dom­ized Phase 2, open-label study in patients with pre­vi­ously-treated mul­ti­ple myeloma that eval­u­ated two doses of the inves­ti­ga­tional mono­clonal anti­body elotuzumab (10 mg/kg and 20 mg/kg) in com­bi­na­tion with lena­lido­mide and low-dose dexa­meth­a­sone. In the 10 mg/kg arm (N=36), which is the dose used in the on­go­ing Phase 3 trials, median pro­gres­sion-free sur­vival (PFS), or the time without dis­ease pro­gres­sion, …